FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Author:
Affiliation:
1. Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA
2. Center for Drug Evaluation and Research, Silver Spring, Maryland, USA
3. Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
Abstract
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2018-0028
Reference20 articles.
1. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2;Morgan;Mol Ther,2010
2. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia;Fitzgerald;Crit Care Med,2017
3. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia;Brentjens;Sci Transl Med,2013
4. Current concepts in the diagnosis and management of cytokine release syndrome;Lee;Blood,2014
5. Toxicities of chimeric antigen receptor T cells: Recognition and management;Brudno;Blood,2016
Cited by 609 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Serial electrical impedance tomography course in different treatment groups; The MaastrICCht cohort;Journal of Critical Care;2024-04
2. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma;Expert Review of Anticancer Therapy;2024-01-15
3. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies;Annals of Laboratory Medicine;2024-01-11
4. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review;BMC Geriatrics;2024-01-08
5. Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond;Advances in Protein Chemistry and Structural Biology;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3